Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials
Astrid E. Persson, Andreas Hallqvist, Louise Bjørn Larsen, Mette Rasmussen, Jonas Scherman, Per Nilsson, Hanne Tønnesen, Adalsteinn Gunnlaugsson · 2024
Read Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials by Astrid E. Persson, Andreas Hallqvist, Louise Bjørn Larsen, Mette Rasmussen, Jonas Scherman, Per Nilsson, Hanne Tønnesen, Adalsteinn Gunnlaugsson (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11654405.txt.
Description
Persson and seven co-authors review trial proof for focused radiation as a treatment for spread prostate cancer, in this 2024 paper. When the cancer has spread to only a few spots, doctors can aim high-dose beams at each spot, a method called SBRT. The hope is to slow the disease without starting lifelong drug therapy.
The team searched four databases and found seven phase two trials with 559 patients in total. Four trials reported clearly longer times before the disease grew, and pooling gave a strong effect in that direction. Severe side effects looked no worse than in control groups. Survival data were still too young to judge, and trial quality ranged from fair to weak. The authors say larger phase three trials, with stronger design, are needed before this becomes standard care.
Catalog record
| CREATOR | Astrid E. Persson, Andreas Hallqvist, Louise Bjørn Larsen, Mette Rasmussen, Jonas Scherman, Per Nilsson, Hanne Tønnesen, Adalsteinn Gunnlaugsson |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 80 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |